CRP and cancer: Our findings suggest that elevated serum Gal-3 levels (≥13.92 ng/mL) might be a candidate biomarker of CRP/cancer development, particularly in the presence of other established factors such as age, body weight, and abdominal obesity, rather than as a standalone discriminator.